Drug Profile


Alternative Names: 497115; Eltrombopag olamine; Promacta; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer GlaxoSmithKline; Novartis; Technische Universitat Dresden
  • Class Benzoates; Hydrazines; Pyrazoles; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 04 Jul 2017 GlaxoSmithKline completes a phase III extension trial for Idiopathic thrombocytopenic purpura (In infants, In children, In adolescents) in Russia (PO) (NCT02201290)
  • 23 Jun 2017 Technische Universität Dresden in collaboration with Novartis initiates enrolment in the DELTA trial for Acute myeloid leukaemia (Adjunctive treatment, In the elderly, In adults, Newly diagnosed) in Germany (PO) (EudraCT2014-003150-13)
  • 01 May 2017 Novartis suspends patient enrolment in the phase II DELTA trial in Acute myeloid leukaemia (Adjunctive treatment, In the elderly, In adults, Newly diagnosed) in Germany (PO) (EudraCT2014-003150-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top